Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

17.08.2018 | short review | Ausgabe 3/2018 Open Access

memo - Magazine of European Medical Oncology 3/2018

Cure in metastatic breast cancer

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2018
Autoren:
Theresa Westphal, Simon Peter Gampenrieder, Gabriel Rinnerthaler, Prof. Richard Greil

Summary

Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several case series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defense by immuno-oncologic drugs can achieve long-lasting tumor control. So far, unfortunately, checkpoint inhibitors as monotherapy have led to responses only in a small percentage of patients with metastatic breast cancer. This short review summarizes available data on long-lasting remissions and potential cure in metastatic breast cancers. It describes and discusses data on locoregional treatment, chemo-, antibody- and immunotherapy and tries to select individual patients for whom a multidisciplinary treatment approach with curative intention might be an option to achieve long-term survival.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2018

memo - Magazine of European Medical Oncology 3/2018 Zur Ausgabe